These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19857110)

  • 1. Bilateral deepening of upper lid sulcus from topical bimatoprost therapy.
    Yam JC; Yuen NS; Chan CW
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):471-2. PubMed ID: 19857110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deepening of lid sulcus from topical bimatoprost therapy.
    Peplinski LS; Albiani Smith K
    Optom Vis Sci; 2004 Aug; 81(8):574-7. PubMed ID: 15300114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs.
    Inoue K; Shiokawa M; Wakakura M; Tomita G
    J Glaucoma; 2013; 22(8):626-31. PubMed ID: 22936280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost.
    Aihara M; Shirato S; Sakata R
    Jpn J Ophthalmol; 2011 Nov; 55(6):600-4. PubMed ID: 21953485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bilateral upper eyelid retraction caused by topical bimatoprost therapy.
    Noma K; Kakizaki H
    Ophthalmic Plast Reconstr Surg; 2012; 28(2):e33-5. PubMed ID: 21562439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recovery from deepening of the upper eyelid sulcus after switching from bimatoprost to latanoprost.
    Sakata R; Shirato S; Miyata K; Aihara M
    Jpn J Ophthalmol; 2013 Mar; 57(2):179-84. PubMed ID: 23233196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical bimatoprost 0.03% and iatrogenic eyelid and orbital lipodystrophy.
    Sira M; Verity DH; Malhotra R
    Aesthet Surg J; 2012 Sep; 32(7):822-4. PubMed ID: 22942109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of deepening of the upper eyelid sulcus after topical use of travoprost ophthalmic solution in Japanese.
    Maruyama K; Shirato S; Tsuchisaka A
    J Glaucoma; 2014 Mar; 23(3):160-3. PubMed ID: 22922663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension.
    Robin AL
    Eur J Ophthalmol; 2007; 17(4):685-6; author reply 686-7. PubMed ID: 17671954
    [No Abstract]   [Full Text] [Related]  

  • 10. Periorbital changes associated with topical bimatoprost.
    Filippopoulos T; Paula JS; Torun N; Hatton MP; Pasquale LR; Grosskreutz CL
    Ophthalmic Plast Reconstr Surg; 2008; 24(4):302-7. PubMed ID: 18645437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the fixed combination of bimatoprost/timolol really produce a better benefit/risk balance than the fixed combination of latanoprost/timolol?
    Soto J; Diaz S
    Eur J Ophthalmol; 2010; 20(1):246-7; author reply 247-8. PubMed ID: 20047180
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost.
    Kucukevcilioglu M; Bayer A; Uysal Y; Altinsoy HI
    Clin Exp Ophthalmol; 2014 Mar; 42(2):126-31. PubMed ID: 23844550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term IOP lowering with bimatoprost in open-angle glaucoma patients poorly responsive to latanoprost.
    Sonty S; Donthamsetti V; Vangipuram G; Ahmad A
    J Ocul Pharmacol Ther; 2008 Oct; 24(5):517-20. PubMed ID: 18800869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bimatoprost 0.01% in treatment-naïve patients with open-angle glaucoma or ocular hypertension: an observational study in the Korean clinical setting.
    Park KH; Simonyi S; Kim CY; Sohn YH; Kook MS
    BMC Ophthalmol; 2014 Dec; 14():160. PubMed ID: 25519810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comment on Efficacy and tolerability of prostaglandin analogs.
    Eisenberg D
    J Glaucoma; 2009 Aug; 18(6):498; author reply 498-9. PubMed ID: 19593206
    [No Abstract]   [Full Text] [Related]  

  • 16. Bimatoprost versus travoprost in an Egyptian population: a hospital-based prospective, randomized study.
    Macky TA
    J Ocul Pharmacol Ther; 2010 Dec; 26(6):605-10. PubMed ID: 21034177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Periocular cutaneous pigmentary changes associated with bimatoprost use.
    Galloway GD; Eke T; Broadway DC
    Arch Ophthalmol; 2005 Nov; 123(11):1609-10. PubMed ID: 16286629
    [No Abstract]   [Full Text] [Related]  

  • 18. Recovery of orbital fat pad prolapsus and deepening of the lid sulcus from topical bimatoprost therapy: 2 case reports and review of the literature.
    Aydin S; Işikligil I; Tekşen YA; Kir E
    Cutan Ocul Toxicol; 2010 Sep; 29(3):212-6. PubMed ID: 20670089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
    García-López A; Paczka JA; Jiménez-Román J; Hartleben C
    BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of bimatoprost monotherapy in primary chronic angle closure and primary open angle glaucoma eyes: a three-year study.
    Gupta V; Srinivasan G; Sharma A; Kapoor KS; Sihota R
    J Ocul Pharmacol Ther; 2007 Aug; 23(4):351-8. PubMed ID: 17803433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.